Table 1 Demographics and clinical characteristics of the patients and CIBMTR controls.

From: Decrease post-transplant relapse using donor-derived expanded NK-cells

 

Cases N (%)

Controls N (%)

MAC controls N (%)

RIC controls N (%)

Number of patients

24

160

81

79

Number of centers

1

61

38

40

Age at transplant, years

 Median (range)

46 (18–60)

44 (19–60)

45 (19–60)

43 (19–61)

 18–30

4 (17)

37 (23)

20 (24)

17 (22)

 31–40

3 (13)

26 (16)

12 (15)

14 (18)

 41–50

8 (33)

31 (19)

15 (19)

16 (20)

 51–60

9 (38)

66 (41)

34 (42)

32 (41)

Gender

 Male

12 (50)

84 (53)

39 (48)

45 (57)

 Female

12 (50)

76 (48)

42 (52)

34 (43)

Race

 Caucasian

17 (71)

89 (56)

47 (58)

42 (53)

 African American

4 (17)

48 (30)

23 (28)

25 (32)

 Asian

2 (8)

13 (8)

6 (7)

7 (9)

 Other

1 (4)

1 (1)

0

1 (1)

 Missing

0

9 (6)

5 (6)

4 (5)

Ethnicity

 Hispanic or Latino

4 (17)

25 (16)

14 (17)

11 (14)

 Non-Hispanic or non-Latino

20 (83)

132 (83)

65 (80)

67 (85)

 Missing

0

3 (2)

2 (2)

1 (1)

Performance score

 90–100

18 (75)

78 (49)

34 (42)

44 (56)

 <90

6 (25)

82 (51)

47 (58)

35 (44)

HCT-CI

 0

5 (21)

30 (19)

12 (15)

18 (23)

 1

3 (13)

29 (18)

14 (17)

15 (19)

 2

4 (17)

31 (19)

15 (19)

16 (20)

 3

6 (25)

31 (19)

21 (26)

10 (13)

 >3

6 (25)

39 (24)

19 (23)

20 (25)

CMV serostatus

 Negative

2 (8)

41 (26)

18 (22)

23 (29)

 Positive

22 (92)

119 (74)

63 (78)

56 (71)

Donor-specific antibodies

5 (21)

35 (22)

18 (22)

17 (22)

Disease

 AML

13 (54)

104 (65)

52 (64)

52 (66)

 CML

7 (29)

24 (15)

13 (16)

11 (14)

 MDS

4 (17)

32 (20)

16 (20)

16 (20)

Cytogenetic risk for AML—number of patientsa

13

136

68

68

 Favorable

0

15 (11)

8 (12)

7 (10)

 Intermediate

6 (46)

77 (57)

35 (51)

42 (62)

 Adverse

7 (54)

38 (28)

22 (32)

16 (24)

 Not reported

0

6 (4)

3 (4)

3 (4)

Disease status at transplant—AML

 First complete remission

10 (77)

80 (77)

40 (77)

40 (77)

 Relapse

3 (23)

24 (23)

12 (23)

12 (23)

Disease status at transplant—CML

 First chronic phase

4 (57)

13 (54)

4 (31)

9 (82)

 Second chronic phase

3 (43)

11 (46)

9 (69)

2 (18)

Disease status at transplant—MDS

 Advanced stage

4 (100)

32 (100)

16 (100)

16 (100)

Graft type

 Bone marrow

24 (100)

42 (26)

15 (19)

27 (34)

 Blood

0

118 (74)

66 (81)

52 (66)

Conditioning intensity

 MAC

0

81 (51)

81

0

 RIC/NMA

24 (100)

79 (49)

0

79

MAC regimens

 TBI + Cy + Flud

0

1 (1)

1 (1)

0

 TBI + Flud

0

39 (48)

39 (48)

0

 TBI + Cy

0

2 (2)

2 (2)

0

 Bu + Cy + Flud

0

17 (21)

17 (21)

0

 Bu + Cy

0

4 (5)

4 (5)

0

 Bu + Flud + Mel

0

2 (2)

2 (2)

0

 Bu + Flud

0

11 (14)

11 (14)

0

 Cy + Flud + Mel

0

2 (2)

2 (2)

0

 Cy + Flud

0

2 (2)

2 (2)

0

 TBI + other

0

1 (1)

1 (1)

0

RIC/NMA regimens

 TBI + Cy + Flud

0

64 (81)

0

64 (81)

 TBI + Flud + Mel

21 (88)

3 (4)

0

3 (4)

 Flud + Mel

3 (13)

3 (4)

0

3 (4)

 TBI + Bu + Flud

0

5 (6)

0

5 (6)

 Bu + Flud

0

2 (3)

0

2 (3)

 Cy + Flud

0

2 (3)

0

2 (3)

GVHD prophylaxis

 PTCy + TAC + MMF

24 (100)

160 (100)

81 (100)

79 (100)

Year of transplant

 2014

2 (8)

27 (17)

14 (17)

13 (16)

 2015

9 (38)

49 (31)

25 (31)

24 (30)

 2016

5 (21)

33 (21)

13 (16)

20 (25)

 2017

4 (17)

33 (21)

19 (23)

14 (18)

 2018

4 (17)

18 (11)

10 (12)

8 (10)

Median follow-up of survivors (range), months

24 (12–51)

36 (3–59)

35 (6–59)

36 (3–49)

  1. MAC myeloablative conditioning, RIC reduced intensity conditioning, HCT-CI hematopoietic cell transplant comorbidity index, CMV cytomegalovirus, AML acute myelogenous leukemia, MDS myelodysplastic syndrome, TBI total body irradiation, Cy cyclophosphamide, Flud fludarabine, Bu busulfan, Mel melphalan, PTCy post-transplant cyclophosphamide, TAC tacrolimus, MMF mycophenolate mofetil.
  2. aCytogenetic risk for AML was defined as follows:
  3. Favorable: t(15:17), inv(16), del(16q), t(16:16), t(8:21) without del(9q) or complex.
  4. Intermediate: normal karyotype, +6, +8, −Y, del(12p), 11q23, t(9:11).
  5. Adverse/poor: complex karyotype, −5/del(5q), −7/del(7q), abnormal (3q, 9q, 11q, 21q, 17p), t(6:9), t(9:22).
Back to article page